For instance, the combination of pembrolizumab, trastuzumab and chemotherapy showed promising efficacy in HER2-positive advanced GC, with an ORR above 74.4% in stage I–III clinical trials, regardless of the PD-L1 status23,24. The gene discussed is ERBB2; the disease is gastric cancer.